Rezdiffra Improved Liver Health Across Genetic Variants
A new analysis shows that patients with common MASH-associated genetic markers saw liver benefits after taking Rezdiffra.
Updated on Oct. 14, 2026 in Diseases — General
Live Poll
Would you want genetic testing results to guide your choice of prescription medications?
Rezdiffra has demonstrated effectiveness in improving liver damage across patients carrying specific genetic variants linked to metabolic dysfunction-associated steatohepatitis (MASH). This secondary analysis of the Phase 3 MAESTRO-NASH trial provides insights for patients managing the disease.
Why it matters
Understanding how genetic differences influence treatment response is crucial for personalizing MASH care. This study helps clinicians identify which patients might see improvements in fibrosis and liver fat when using this therapy.
A secondary analysis of the Phase 3 MAESTRO-NASH trial examined outcomes for patients carrying variants in the PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7 genes. The findings demonstrate that Rezdiffra treatment is associated with improvements in liver fibrosis and reduction of liver fat.
The players
Madrigal Pharmaceuticals
A Conshohocken, Pennsylvania-based biopharmaceutical company focused on developing therapies for liver diseases.
Journal of Hepatology
A peer-reviewed medical publication that serves as a primary source for research in liver health and disease.
The details
Researchers evaluated how common genetic predispositions for MASH progression impact the efficacy of Rezdiffra. By analyzing data from patients with variants in five specific genes, the study confirmed that the treatment consistently helped reduce liver fat as measured by MRI-PDFF. This demonstrates that the therapy remains effective even in individuals with a higher genetic risk for rapid disease progression.
Timeline
October 14, 2026: Findings from the secondary analysis were published in the Journal of Hepatology.
Health Landscape
This analysis extends the findings of the Phase 3 MAESTRO-NASH trial by characterizing the drug's performance against specific genetic risk markers. It contributes to a growing trend of precision medicine in hepatology, moving beyond broad treatment standards.
If you are managing MASH, this research suggests that genetic predispositions do not necessarily limit the benefits of current treatments. It is worth discussing your specific medical history and potential treatment options with your physician to understand if this approach is appropriate for you.
The takeaway
The study suggests that Rezdiffra can be an effective option for patients even if they carry common genetic risk variants for MASH. Patients should talk with their gastroenterologist or hepatologist about whether genetic testing or targeted monitoring is right for their care plan.
Further reading
For more on managing chronic liver conditions, visit the Diseases — General section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Would you want genetic testing results to guide your choice of prescription medications?
